An investigational oral peptide may improve regional fat distribution and selected metabolic markers in patients with obesity without significant weight loss.
In a randomized, double-blind, placebo-controlled trial, researchers randomly assigned 60 patients aged 21 to 60 years with obesity and a body mass index (BMI) of 30 to 39.9 kg/m² to receive oral Pep19 at 5 mg, Pep19 at 10 mg, or placebo once daily at bedtime for 90 days between April and November 2025. Among the patients, 56 completed the intervention and were included in the final analysis: 18 received placebo, 20 received Pep19 at 5 mg, and 18 received Pep19 at 10 mg.
The prespecified primary endpoint was the between-group difference in the change from baseline to day 90 in the android-to-gynoid fat ratio, assessed using dual-energy X-ray absorptiometry (DXA). Secondary endpoints included body weight, total and regional fat mass, lean mass, glycated hemoglobin, insulin resistance, lipid profiles, inflammatory biomarkers, and safety measures. Assessments were performed at baseline and at days 30, 60, and 90, with DXA imaging conducted at baseline and last follow-up.
At day 90, patients receiving Pep19 at 10 mg demonstrated a greater reduction in the android-to-gynoid fat ratio compared with placebo. The adjusted between-group difference was a reduction of 3.58 percentage points, with the ratio declining to 97% of baseline in the 10-mg group vs. 100% in the placebo group. The 5-mg dose did not significantly affect the primary endpoint.
The higher dose was associated with reductions in abdominal and total skinfold thickness. Mean abdominal skinfold thickness decreased from 37.20 mm at baseline to 31.57 mm at day 90 in the 10-mg group vs. 35.44 mm to 34.94 mm in the placebo group. Body weight, BMI, total fat mass, and lean mass did not differ significantly among treatment groups, indicating that changes in regional adiposity occurred without substantial changes in overall body composition.
Pep19 treatment was associated with improvements in selected measures of glucose regulation. At day 90, mean glycated hemoglobin (HbA1c) was 5.22% in the 10-mg group vs. 5.38% in the placebo group. Relative to baseline, HbA1c declined to 94% of its initial value in the 10-mg group vs. 101% in the placebo group. Fasting glucose concentrations remained unchanged.
Insulin resistance, assessed using the homeostatic model assessment of insulin resistance (HOMA-IR), also improved in both Pep19 groups. At day 90, mean HOMA-IR values were 3.85 in the 10-mg group and 3.21 in the 5-mg group vs. 5.17 in the placebo group. Statistically significant reductions were observed by day 60 with the higher dose and persisted through day 90, whereas the lower dose showed a statistically significant reduction at day 90.
An exploratory cluster analysis identified 11 patients with more pronounced changes in adiposity and metabolic measures who received Pep19, including 6 in the 5-mg group and 5 in the 10-mg group. They demonstrated reductions in total fat mass, abdominal skinfold thickness, overall skinfold measurements, and HOMA-IR, accompanied by lower tumor necrosis factor-alpha levels. The remaining 45 patients showed modest changes. The findings may indicate a subgroup with greater metabolic responsiveness to Pep19.
Other metabolic and cardiovascular measures remained unchanged. No statistically significant between-group differences were observed in lipid profiles, inflammatory biomarkers, or blood pressure. Reported dietary intake and physical activity remained stable throughout the intervention. Safety assessments identified no treatment-related toxicologic signals or clinically relevant laboratory abnormalities during the 90-day treatment period.
The study had several limitations. The modest sample size and short follow-up restricted assessment of long-term efficacy, safety, and clinical relevance. Although the primary endpoint reached statistical significance when expressed as a percentage of baseline, the supporting absolute-scale analysis did not. Improvements in HbA1c and HOMA-IR were secondary outcomes and should be considered exploratory. Baseline insulin resistance indices were higher in the 10-mg group, potentially influencing the magnitude of observed changes. Dietary intake and physical activity were not objectively monitored, and the researchers did not assess target engagement or other mechanistic biomarkers. The exploratory responder analysis and recruitment from a single geographic setting also limit generalizability.
Larger and longer-term trials are needed to determine whether these changes persist and translate into meaningful cardiometabolic benefits.
"Thus, the present study provides evidence supporting improved metabolic regulation rather than definitive proof of improved insulin sensitivity," wrote lead study author Davi Vantini, of Centro Universitário FMABC in Brazil, and colleagues.
Full disclosures of the study authors can be found in the study.
Source: iScience
